Videos
January 14, 2021
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.
Podcast
January 14, 2021
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Videos
January 14, 2021
Christopher Yasenchak, MD, discusses real-world adherence to NCCN guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Videos
January 14, 2021
Mitul Gandhi, MD, discusses results from a study exploring real-world data on patient and provider preferences of rituximab administration for NHL.
Conference Coverage
December 22, 2020
Findings from a single center study show that the outpatient setting is safe, effective, and reduces the total length of hospital stay and overall cost of transplant for adult patients with MM.
Conference Coverage
December 21, 2020
A recent study assessed the comparative efficacy and cost-effectiveness of daratumumab plus pomalidomide and dexamethasone versus isatuximab plus pomalidomide and dexamethasone for relapsed/refractory MM.
Videos
December 21, 2020
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for relapsed/refractory AML outside the trial setting.
Videos
December 20, 2020
Patrick Connor Johnson, MD, discusses results from a retrospective analysis evaluating HCRU and end-of-life outcomes in patients with hematologic malignancies receiving CAR-T therapy.
Videos
December 20, 2020
Robert Rifkin, MD, discusses results from the TOURMALINE-MM2 trial which compared ixazomib, lenalidomide, and dexamethasone (IRd) versus placebo-Rd for transplant-ineligible patients with newly diagnosed MM.
Conference Coverage
December 18, 2020
MRD status in peripheral blood or bone marrow prior to autoSCT is an early predictor of PFS and OS in younger patients with MCL.
Videos
December 17, 2020
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Videos
December 17, 2020
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Videos
December 17, 2020
John Allan, MD, discusses results from analysis exploring the long-term efficacy of first-line ibrutinib in patients with CLL harboring TP53 mutations.
Conference Coverage
December 14, 2020
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Conference Coverage
December 11, 2020
Rituximab monotherapy improves time-to-next treatment (TTNT) compared with observation in patients with advanced stage follicular lymphoma.
Podcast
December 10, 2020
Jan Burger, MD, PhD, discusses an analysis of the RESONATE-2 and iLLUMINATE studies, which explored outcomes of first-line ibrutinib in patients with CLL/SLL and high-risk genomic features.
Conference Coverage
December 10, 2020
Acalabrutinib is more cost-effective and associated with better clinical outcomes compared with ibrutinib and zanubrutinib for relapsed/refractory MCL.
Conference Coverage
December 09, 2020
Study finds higher risk of atrial fibrillation among patients treated with single-agent ibrutinib for CLL or SLL in the real-world setting than in clinical trials.
Videos
December 09, 2020
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing DRd to DPd for lenalidomide-exposed patients with relapsed/refractory MM at Mayo Clinic.
Conference Coverage
December 09, 2020
The addition of rituximab to anthracycline-based chemotherapy demonstrates improved PFS and OS in FL, according to a 35-year follow-up analysis.
Videos
December 09, 2020
Karl Kilgore, PhD, discusses study results comparing patient characteristics, treatments, costs, and OS between Medicare beneficiaries with LBCL who received transplantation versus those who did not.
Videos
December 09, 2020
Parameswaran Hari, MBBS, MD, discusses study results estimating the costs associated with CRS and neurotoxicity management for patients with relapsed/refractory MM who received CAR-T therapy in the KarMMa trial.
Conference Coverage
December 08, 2020
A proposed MRD decision framework at Emory demonstrates cost savings and improved health outcomes for patients with MM initiating maintenance therapy.
Conference Coverage
December 08, 2020
Use of maintenance therapy following autologous stem cell transplantation for MM has increased in routine clinical practice in the US and is associated with longer time to next treatment.
Videos
December 08, 2020
Peter Voorhees, MD, presents updated efficacy and safety results from the GRIFFIN study, following 12 months of maintenance therapy with lenalidomide or daratumumab plus lenalidomide, bortezomib, and dexamethasone (VRd) for patients with newly diagnosed MM.
Videos
December 07, 2020
Raymond Comenzo, MD, discusses results from the ANDROMEDA trial, which show the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone (VCd) improved the rate of deep hematologic responses in patients with newly diagnosed light-chain (AL) amyloidosis.
Conference Coverage
December 07, 2020
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
Conference Coverage
December 06, 2020
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Podcast
December 06, 2020
Lori Leslie, MD, discusses results from a real-world study evaluating clinical outcomes in high-risk and non-high-risk CLL.
Conference Coverage
December 06, 2020
Study results show polatuzumab vedotin plus bendamustine-rituximab is cost-effective in comparison to bendamustine-rituximab alone for relapsed/refractory DLBCL in the US.
Conference Coverage
December 05, 2020
For patients with CML, switching to the subsequent lines of therapy is frequent due to previous TKI intolerance and results in high medical costs.
Videos
December 05, 2020
Robert Rifkin, MD, discusses the ongoing, phase 3 DREAMM-7 study exploring belantamab mafodotin in combination with bortezomib and dexamethasone for patients with relapsed/refractory MM.
Videos
December 05, 2020
Meletios Dimopoulos, MD, discusses results from the phase 3 APOLLO study, which compared subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone for relapsed/refractory MM.
Conference Coverage
December 04, 2020
Ibrutinib dose reductions and discontinuations due to adverse events are higher in routine clinical practice than in clinical trials, according to results from a study presented at the ASH Annual Meeting.
Conference Coverage
December 04, 2020
Study findings show patients with advanced FL who received initial treatment had better OS compared to those managed using watch and wait.
Conference Coverage
November 30, 2020
The use of 90 Y-ibritumomab tiuxetan in consolidation or second-line treatment of relapsed or refractory FL demonstrated desired patient outcomes at one of the lowest cost profiles.